Read More

UPDATE: Satsuma Says ‘All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile’; Co Initiating Phase 3 Efficacy Trial In Acute Treatment Of Migra…

- All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile - - Initiating SUMMIT Phase 3 efficacy trial to

STSA